Mounjaro/Zepbound LT safety question? Paper on anti-drug antibodies, including a small incidence of neutralizing antibodies against native GLP-1/GIP:
Interesting paper:
Tirzepatide immunogenicity post-treatment.
- >50% of pts develop ADA against TZP - 2% has neutralizing Ab against TZP activity at GIPr & GLP1r - MOST interestingly, 0.9% develop NAb against native GIP & 0.4% NAb against nGLP-1!https://t.co/2WANUFZpT8pic.twitter.com/Reb1nVhy7f